- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Endomagnetics, the company developing advanced magnetic sensing technology for use in breast cancer staging, has achieved CE approval for the sale of its magnetic tracer material, branded Sienna+™. The injectable tracer is used in combination with the ultra-sensitive SentiMag® instrument in sentinel lymph node biopsy (SLNB), currently the standard of care in tracking the spread of breast cancer.
The SentiMag® instrument itself has also been CE approved, so clinicians across Europe now have available a complete system to be used in place of conventional radioisotopes. The need for special handling of radioactive materials means that many hospitals and clinics are not able to use them. As a result, as many as half of the patients in the West who would benefit from the SLNB technique are not able to access it, and availability is much worse still in other parts of the world.
Endomagnetics' development of the SentiMag® and Sienna+™ system allows best practice SLNB to be performed anywhere, by any practitioner, without substantially changing their working practice. The combined system offers reduced workflow complexity with a corresponding reduction in procedural cost.
"Achievement of CE approval for Sienna+™ is an important milestone for Endomagnetics and our ability to deliver a complete solution to the market," says Dr Eric Mayes, CEO of Endomagnetics. "It demonstrates that the system has met rigorous EU safety, health and environmental requirements."
Endomagnetics recently showed its technology at the San Antonio Breast Cancer Symposium and received an enthusiastic reception from oncologists and surgeons from many countries.
Endomagnetics was founded to solve cancer staging and healthcare challenges through the application of advanced magnetic sensing technology and nanotechnology. Endomagnetics is developing a portfolio of medical device products based on a patented ability to detect magnetic materials in the human body with exceptional sensitivity. The technology was originally developed at University College London and the University of Houston.
The company’s first product, the SentiMag®, is an ultrasensitive hand-held probe for tracking injected Sienna+™ nanoscale magnetic materials in the human body. Cambridge, UK-based Endomagnetics is in the process of delivering its technology to global markets.
For more information, please click here
Tel: +44 (0)7923 540695
Dr Eric Mayes
Tel: +44 (0)1223 437131
Copyright © EndomagneticsIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Leti IEDM 2016 Paper Clarifies Correlation between Endurance, Window Margin and Retention in RRAM for First Time: Paper Presented at IEDM 2016 Offers Ways to Reconcile High-cycling Requirements and Instability at High Temperatures in Resistive RAM December 6th, 2016
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016